Pediatrix Medical Group, Inc.

For the period ended Mar 31, 2026. Filed May 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 5, 2026

MD$31.29-1.7%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025 (Unaudited)

Consolidated Balance Sheets

(in thousands, except share data)

	March 31, 2026	December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents	$205,780	$375,241
Short-term investments	123,194	124,482
Accounts receivable, net	224,801	229,665
Prepaid expenses	12,866	12,606
Income taxes receivable	12,188	12,641
Other current assets	8,205	8,879
Total current assets	587,034	763,514
Property and equipment, net	41,094	39,180
Goodwill	1,268,248	1,260,732
Intangible assets, net	15,937	16,862
Operating and finance lease right-of-use assets	36,871	34,330
Deferred income tax assets	65,708	73,922
Other assets	55,403	58,156
Total assets	$2,070,295	$2,246,696
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses	$236,930	$419,530
Current portion of debt and finance lease liabilities, net	192,421	26,806
Current portion of operating lease liabilities	11,885	11,591
Income taxes payable	1,402	984
Total current liabilities	442,638	458,911
Long-term debt and finance lease liabilities, net	398,348	570,532
Long-term operating lease liabilities	27,061	25,686
Long-term professional liabilities	236,949	238,353
Deferred income tax liabilities	57,002	57,024
Other liabilities	29,721	30,336
Total liabilities	1,191,719	1,380,842
Commitments and contingencies
Shareholders’ equity:
Preferred stock; $.01 par value; 1,000,000 shares authorized; none issued	—	—
Common stock; $.01 par value; 200,000,000 shares authorized; 82,061,119 and 82,976,110 shares issued and outstanding, respectively	821	830
Additional paid-in capital	931,258	947,566
Accumulated other comprehensive income	77	610
Retained deficit	(53,580)	(83,152)
Total shareholders’ equity	878,576	865,854
Total liabilities and shareholders’ equity	$2,070,295	$2,246,696

Consolidated Statements of Income and Comprehensive Income

(in thousands, except per share data)

	Three Months EndedMarch 31,
	2026	2025
Net revenue	$476,196	$458,359
Operating expenses:
Practice salaries and benefits	345,744	337,031
Practice supplies and other operating expenses	17,488	18,686
General and administrative expenses	60,266	58,604
Depreciation and amortization	6,119	5,332
Transformational and restructuring related expenses	4,922	6,605
Total operating expenses	434,539	426,258
Income from operations	41,657	32,101
Investment and other income	4,760	4,737
Interest expense	(8,265)	(9,154)
Equity in earnings of unconsolidated affiliate	692	406
Total non-operating expenses	(2,813)	(4,011)
Income before income taxes	38,844	28,090
Income tax provision	(9,272)	(7,353)
Net income	$29,572	$20,737
Other comprehensive income, net of tax
Unrealized holding (loss) gain on investments, net of tax of $152 and $255	(533)	779
Total comprehensive income	$29,039	$21,516
Per common and common equivalent share data:
Net income:
Basic	$0.37	$0.25
Diluted	$0.36	$0.24
Weighted average common shares:
Basic	80,881	84,435
Diluted	83,075	85,430

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.